

# Moti Kashyap

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2419744/publications.pdf>

Version: 2024-02-01

152  
papers

11,443  
citations

28274

55  
h-index

29157

104  
g-index

158  
all docs

158  
docs citations

158  
times ranked

7373  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. <i>Lancet, The</i> , 2019, 394, 121-130.	13.7	1,625
2	Relation of Gemfibrozil Treatment and Lipid Levels With Major Coronary Events. <i>JAMA - Journal of the American Medical Association</i> , 2001, 285, 1585.	7.4	843
3	Interchange of Apolipoproteins between Chylomicrons and High Density Lipoproteins during Alimentary Lipemia in Man. <i>Journal of Clinical Investigation</i> , 1973, 52, 32-38.	8.2	500
4	Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. <i>Lancet, The</i> , 2019, 394, 131-138.	13.7	394
5	Mechanism of Action of Niacin. <i>American Journal of Cardiology</i> , 2008, 101, S20-S26.	1.6	351
6	Relationship of Apolipoproteins A-1 and B, and Lipoprotein(a) to Cardiovascular Outcomes. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1575-1579.	2.8	258
7	Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. <i>Metabolism: Clinical and Experimental</i> , 1998, 47, 1097-1104.	3.4	222
8	Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia**A complete list of participants in the Research Group and Publication Committee appears in the Appendix.. <i>American Journal of Cardiology</i> , 2002, 89, 672-678.	1.6	221
9	Distribution of lipids in 8,500 men with coronary artery disease. <i>American Journal of Cardiology</i> , 1995, 75, 1196-1201.	1.6	219
10	Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. <i>Journal of Lipid Research</i> , 2004, 45, 1835-1845.	4.2	190
11	Niacin Decreases Removal of High-Density Lipoprotein Apolipoprotein A-I But Not Cholesterol Ester by Hep G2 Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 2020-2028.	2.4	189
12	Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. <i>Atherosclerosis</i> , 2009, 202, 68-75.	0.8	184
13	Mechanism of action of gemfibrozil on lipoprotein metabolism.. <i>Journal of Clinical Investigation</i> , 1985, 75, 1702-1712.	8.2	179
14	Relationship of Lipoproteins to Cardiovascular Events. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1580-1584.	2.8	156
15	Extended-Release Niacin vs Gemfibrozil for the Treatment of Low Levels of High-Density Lipoprotein Cholesterol. <i>Archives of Internal Medicine</i> , 2000, 160, 1177.	3.8	147
16	Niacin therapy in atherosclerosis. <i>Current Opinion in Lipidology</i> , 2004, 15, 659-665.	2.7	147
17	Comparison of Once-Daily, niacin Extended-Release/lovastatin with standard doses of atorvastatin and simvastatin (the advicor versus other Cholesterol-Modulating agents trial evaluation) Tj ETQq1 1 0.784314 rgBILd Overload 140 Tf 50		
18	Niacin and cholesterol: role in cardiovascular disease (review). <i>Journal of Nutritional Biochemistry</i> , 2003, 14, 298-305.	4.2	143

#	ARTICLE	IF	CITATIONS
19	Radioimmunoassay of Human Apolipoprotein CII. <i>Journal of Clinical Investigation</i> , 1977, 60, 171-180.	8.2	137
20	Mechanism of action of niacin on lipoprotein metabolism. <i>Current Atherosclerosis Reports</i> , 2000, 2, 36-46.	4.8	136
21	Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). <i>Atherosclerosis</i> , 2007, 192, 432-437.	0.8	135
22	Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man. <i>Thrombosis Research</i> , 1985, 39, 1-8.	1.7	126
23	Niacin Accelerates Intracellular ApoB Degradation by Inhibiting Triacylglycerol Synthesis in Human Hepatoblastoma (HepG2) Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 1051-1059.	2.4	120
24	The mechanism and mitigation of niacin-induced flushing. <i>International Journal of Clinical Practice</i> , 2009, 63, 1369-1377.	1.7	115
25	Niacin, but Not Gemfibrozil, Selectively Increases LP-AI, a Cardioprotective Subfraction of HDL, in Patients With Low HDL Cholesterol. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 1783-1789.	2.4	112
26	A rapid and simple method for measurement of total protein in very low density lipoproteins by the Lowry assay. <i>Journal of Lipid Research</i> , 1980, 21, 491-495.	4.2	112
27	Apolipoprotein C-II deficiency syndrome. Clinical features, lipoprotein characterization, lipase activity, and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients.. <i>Journal of Clinical Investigation</i> , 1986, 77, 520-527.	8.2	110
28	Reverse Epidemiology of Traditional Cardiovascular Risk Factors in the Geriatric Population. <i>Journal of the American Medical Directors Association</i> , 2015, 16, 933-939.	2.5	102
29	Familial apolipoprotein A-I and C-III deficiency, variant II.. <i>Journal of Lipid Research</i> , 1985, 26, 1089-1101.	4.2	90
30	Estradiol, testosterone, apolipoproteins, lipoprotein cholesterol, and lipolytic enzymes in men with premature myocardial infarction and angiographically assessed coronary occlusion. <i>Artery</i> , 1983, 12, 1-23.	1.6	89
31	Niacin inhibits fat accumulation, oxidative stress, and inflammatory cytokine IL-8 in cultured hepatocytes: Impact on non-alcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 982-990.	3.4	88
32	Niacin inhibits surface expression of ATP synthase $\hat{F}_2$ chain in HepG2 cells: implications for raising HDL. <i>Journal of Lipid Research</i> , 2008, 49, 1195-1201.	4.2	86
33	The benefits of niacin in atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2001, 3, 74-82.	4.8	84
34	Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1554-1562.	0.7	84
35	A rapid and simple method for measurement of total protein in very low density lipoproteins by the Lowry assay. <i>Journal of Lipid Research</i> , 1980, 21, 491-5.	4.2	82
36	Hyperalpha- and hypobeta-lipoproteinemia in octogenarian kindreds. <i>Atherosclerosis</i> , 1977, 27, 387-406.	0.8	78

#	ARTICLE	IF	CITATIONS
37	Quantitation of human apolipoprotein C-III and its subspecies by radioimmunoassay and analytical isoelectric focusing: abnormal plasma triglyceride-rich lipoprotein apolipoprotein C-III subspecies concentrations in hypertriglyceridemia. <i>Journal of Lipid Research</i> , 1981, 22, 800-810.	4.2	76
38	Increased reverse cholesterol transport in athletes. <i>Metabolism: Clinical and Experimental</i> , 1993, 42, 684-690.	3.4	75
39	High density lipoproteinuria in nephrotic syndrome. <i>Metabolism: Clinical and Experimental</i> , 1976, 25, 1143-1149.	3.4	74
40	Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: A phase 3 study. <i>Atherosclerosis</i> , 2009, 204, 208-215.	0.8	74
41	Safety Profile of Extended-Release Niacin in the AIM-HIGH Trial. <i>New England Journal of Medicine</i> , 2014, 371, 288-290.	27.0	73
42	LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease. <i>Journal of Cardiac Failure</i> , 2018, 24, 266-275.	1.7	71
43	Familial apolipoprotein A-I and C-III deficiency, variant II. <i>Journal of Lipid Research</i> , 1985, 26, 1089-101.	4.2	71
44	Recent advances in niacin and lipid metabolism. <i>Current Opinion in Lipidology</i> , 2013, 24, 239-245.	2.7	70
45	Influence of polyunsaturated and saturated fats on plasma lipids and lipoproteins in man. <i>American Journal of Clinical Nutrition</i> , 1984, 39, 589-597.	4.7	65
46	Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 306, G320-G327.	3.4	63
47	Apolipoprotein CII and lipoprotein lipase in human nephrotic syndrome. <i>Atherosclerosis</i> , 1980, 35, 29-40.	0.8	60
48	Ethanol stimulates apolipoprotein A-I secretion by human hepatocytes: Implications for a mechanism for atherosclerosis protection. <i>Metabolism: Clinical and Experimental</i> , 1992, 41, 827-832.	3.4	60
49	Efficacy and Safety of Controlled-Release Niacin in Dyslipoproteinemic Veterans. <i>Annals of Internal Medicine</i> , 1994, 121, 252.	3.9	60
50	Role of HDL Dysfunction in End-Stage Renal Disease: A Double-Edged Sword. , 2013, 23, 203-206.		60
51	Alimentary lipemia: plasma high-density lipoproteins and apolipoproteins CII and CIII in healthy subjects. <i>American Journal of Clinical Nutrition</i> , 1983, 37, 233-243.	4.7	59
52	Apolipoprotein AI and AII metabolism in patients with primary high-density lipoprotein deficiency associated with familial hypertriglyceridemia. <i>Metabolism: Clinical and Experimental</i> , 1985, 34, 754-764.	3.4	58
53	Quantitation of human apolipoprotein C-III and its subspecies by radioimmunoassay and analytical isoelectric focusing: abnormal plasma triglyceride-rich lipoprotein apolipoprotein C-III subspecies concentrations in hypertriglyceridemia. <i>Journal of Lipid Research</i> , 1981, 22, 800-10.	4.2	58
54	Effects of dietary carbohydrate and fat on plasma lipoproteins and apolipoproteins C-II and C-III in healthy men. <i>Journal of Lipid Research</i> , 1982, 23, 877-886.	4.2	56

#	ARTICLE	IF	CITATIONS
55	Nicotinic Acid (Niacin) Receptor Agonists: Will They Be Useful Therapeutic Agents?. American Journal of Cardiology, 2007, 100, S53-S61.	1.6	55
56	Long-Term Safety and Efficacy of a Combination of Niacin Extended Release and Simvastatin in Patients with Dyslipidemia. American Journal of Cardiovascular Drugs, 2008, 8, 69-81.	2.2	55
57	C-II anapolipoproteinemia and severe hypertriglyceridemia. American Journal of Medicine, 1984, 77, 457-462.	1.5	53
58	Pharmacologic elevation of high-density lipoproteins: recent insights on mechanism of action and atherosclerosis protection. Current Opinion in Cardiology, 2004, 19, 366-373.	1.8	51
59	Abnormal preponderance of sialylated apolipoprotein CIII in triglyceride rich lipoproteins in type V hyperlipoproteinemia. Metabolism: Clinical and Experimental, 1981, 30, 111-118.	3.4	50
60	Comparison of intraperitoneal and subcutaneous insulin administration on lipids, apolipoproteins, fuel metabolites, and hormones in type I diabetes mellitus. Metabolism: Clinical and Experimental, 1989, 38, 908-912.	3.4	50
61	Relationship between Post-Heparin Plasma Lipases, Triglycerides and High Density Lipoproteins in Normal Subjects. Hormone and Metabolic Research, 1990, 22, 289-294.	1.5	48
62	Niacin, lipids, and heart disease. Current Cardiology Reports, 2003, 5, 470-476.	2.9	48
63	Basic considerations in the reversal of atherosclerosis: Significance of high-density lipoprotein in stimulating reverse cholesterol transport. American Journal of Cardiology, 1989, 63, 56-59.	1.6	46
64	Nicotinic acid induces secretion of prostaglandin D2 in human macrophages: An in vitro model of the niacin flush. Atherosclerosis, 2007, 192, 253-258.	0.8	45
65	Mechanistic studies of high-density lipoproteins. American Journal of Cardiology, 1998, 82, 42U-48U.	1.6	44
66	Post-heparin plasma lipoprotein and hepatic lipases. Atherosclerosis, 1980, 37, 247-256.	0.8	43
67	Effects of apolipoprotein C-II (apoC-II) on the lipolysis of very low density lipoproteins from apoC-II deficient patients. Metabolism: Clinical and Experimental, 1981, 30, 818-824.	3.4	43
68	Dietitian Intervention Improves Lipid Values and Saves Medication Costs in Men with Combined Hyperlipidemia and a History of Niacin Noncompliance. Journal of the American Dietetic Association, 2000, 100, 218-224.	1.1	43
69	Niacin increases HDL biogenesis by enhancing DR4-dependent transcription of ABCA1 and lipidation of apolipoprotein A-I in HepG2 cells. Journal of Lipid Research, 2012, 53, 941-950.	4.2	43
70	High density lipoproteins stimulate the production and secretion of endothelin-1 from cultured bovine aortic endothelial cells.. Journal of Clinical Investigation, 1994, 93, 1056-1062.	8.2	43
71	Association of Serum Triglyceride to HDL Cholesterol Ratio with All-Cause and Cardiovascular Mortality in Incident Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 591-602.	4.5	42
72	Apolipoproteins A-I and B and cholesterol in synovial fluid of patients with rheumatoid arthritis. Metabolism: Clinical and Experimental, 1993, 42, 803-806.	3.4	41

#	ARTICLE	IF	CITATIONS
73	Medical Nutrition Therapy Lowers Serum Cholesterol and Saves Medication Costs in Men with Hypercholesterolemia. <i>Journal of the American Dietetic Association</i> , 1998, 98, 889-894.	1.1	39
74	Mechanism and regulation of human intestinal niacin uptake. <i>American Journal of Physiology - Cell Physiology</i> , 2005, 289, C97-C103.	4.6	39
75	Effects of dietary carbohydrate and fat on plasma lipoproteins and apolipoproteins C-II and C-III in healthy men. <i>Journal of Lipid Research</i> , 1982, 23, 877-86.	4.2	38
76	Niacin for treatment of nonalcoholic fatty liver disease (NAFLD): novel use for an old drug?. <i>Journal of Clinical Lipidology</i> , 2019, 13, 873-879.	1.5	37
77	Mechanism of nicotinic acid transport in human liver cells: experiments with HepG2 cells and primary hepatocytes. <i>American Journal of Physiology - Cell Physiology</i> , 2007, 293, C1773-C1778.	4.6	35
78	Pioglitazone Stimulates Apolipoprotein A-I Production Without Affecting HDL Removal in HepG2 Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 2428-2434.	2.4	35
79	In vitro catabolism of human plasma very low density lipoproteins. <i>Atherosclerosis</i> , 1982, 41, 381-394.	0.8	34
80	Niacin: An old drug rejuvenated. <i>Current Atherosclerosis Reports</i> , 2009, 11, 45-51.	4.8	34
81	Hydrolysis of guinea pig nascent very low density lipoproteins catalyzed by lipoprotein lipase: activation by human apolipoprotein C-II. <i>Journal of Lipid Research</i> , 1981, 22, 921-933.	4.2	34
82	Uremic serum subfraction inhibits apolipoprotein A-I production by a human hepatoma cell line. <i>Journal of the American Society of Nephrology: JASN</i> , 1994, 5, 193-200.	6.1	34
83	Pharmacologic Treatment of Type 2 Diabetic Dyslipidemia. <i>Pharmacotherapy</i> , 2004, 24, 1692-1713.	2.6	33
84	Nicotinic acid: recent developments. <i>Current Opinion in Cardiology</i> , 2008, 23, 393-398.	1.8	33
85	Estradiol Stimulates Apolipoprotein A-I but Not A-II-Containing Particle Synthesis and Secretion by Stimulating mRNA Transcription Rate in Hep G2 Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998, 18, 999-1006.	2.4	31
86	Gemfibrozil Stimulates Apolipoprotein A-I Synthesis and Secretion by Stabilization of mRNA Transcripts in Human Hepatoblastoma Cell Line (Hep G2). <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1996, 16, 1052-1062.	2.4	28
87	Reverse D4F, an Apolipoprotein-AI Mimetic Peptide, Inhibits Atherosclerosis in ApoE-null Mice. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2012, 17, 334-343.	2.0	27
88	Composition of HDL-2 and HDL-3 in familial hyperalphalipoproteinemia. <i>Atherosclerosis</i> , 1976, 25, 131-136.	0.8	26
89	Carbohydrate and lipid metabolism during human labor: Free fatty acids, glucose, insulin, and lactic acid metabolism during normal and oxytocin-induced labor for postmaturity. <i>Metabolism: Clinical and Experimental</i> , 1976, 25, 865-875.	3.4	25
90	Niacin extended-release/ lovastatin: combination therapy for lipid disorders. <i>Expert Opinion on Pharmacotherapy</i> , 2002, 3, 1763-1771.	1.8	25

#	ARTICLE	IF	CITATIONS
91	Management of the metabolic syndrome—nicotinic acid. <i>Endocrinology and Metabolism Clinics of North America</i> , 2004, 33, 557-575.	3.2	25
92	Niacin and Progression of CKD. <i>American Journal of Kidney Diseases</i> , 2015, 65, 785-798.	1.9	24
93	The role of high density lipoprotein apolipoprotein CII in triglyceride metabolism. <i>Lipids</i> , 1978, 13, 933-942.	1.7	23
94	Cardiovascular disease in the elderly: Current considerations. <i>American Journal of Cardiology</i> , 1989, 63, 3-4.	1.6	23
95	Effect of gemfibrozil on apolipoprotein B secretion and diacylglycerol acyltransferase activity in human hepatoblastoma (HepG2) cells. <i>Atherosclerosis</i> , 2002, 164, 221-228.	0.8	23
96	Pioglitazone increases apolipoprotein A-I production by directly enhancing PPRE-dependent transcription in HepG2 cells. <i>Journal of Lipid Research</i> , 2010, 51, 2211-2222.	4.2	23
97	Lipoprotein lipase activator deficiency in very low density lipoproteins in rat nephrotic syndrome. <i>Experientia</i> , 1978, 34, 1044-1045.	1.2	21
98	Human plasma lipid transfer protein catalyzes the speciation of high density lipoproteins. <i>Lipids and Lipid Metabolism</i> , 1987, 918, 260-266.	2.6	21
99	Renal handling of high-density lipoproteins by isolated perfused kidneys. <i>Metabolism: Clinical and Experimental</i> , 1984, 33, 432-438.	3.4	20
100	Effect of niacin on lipoproteins and atherosclerosis. <i>Future Lipidology</i> , 2006, 1, 549-557.	0.5	20
101	Baseline Achievement of Lipid Goals and Usage of Lipid Medications in Patients With Diabetes Mellitus (from the Veterans Affairs Diabetes Trial). <i>American Journal of Cardiology</i> , 2006, 98, 63-65.	1.6	20
102	Inverse Association Between Serum Non-High-Density Lipoprotein Cholesterol Levels and Mortality in Patients Undergoing Incident Hemodialysis. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	20
103	Diet and HDL Metabolism: High Carbohydrate vs. High Fat Diets. <i>Advances in Experimental Medicine and Biology</i> , 1987, 210, 165-172.	1.6	20
104	High-Density Lipoprotein Apolipoprotein AI and All Turnover in Moderate and Severe Proteinuria. <i>Nephron</i> , 1988, 50, 112-115.	1.8	19
105	Association of Serum Lipids with Outcomes in Hispanic Hemodialysis Patients of the West versus East Coasts of the United States. <i>American Journal of Nephrology</i> , 2015, 41, 284-295.	3.1	19
106	Comparison of gradient gel electrophoresis and zonal ultracentrifugation for quantitation of high density lipoproteins. <i>Journal of Lipid Research</i> , 1985, 26, 1363-1367.	4.2	19
107	Acetylsalicylic Acid Reduces Niacin Extended-Release-Induced Flushing in Patients with Dyslipidemia. <i>American Journal of Cardiovascular Drugs</i> , 2009, 9, 69-79.	2.2	18
108	Rosuvastatin selectively stimulates apolipoprotein A-I but not apolipoprotein A-II synthesis in Hep G2 cells. <i>Metabolism: Clinical and Experimental</i> , 2008, 57, 973-979.	3.4	17



#	ARTICLE	IF	CITATIONS
109	Mammalian colonocytes possess a carrier-mediated mechanism for uptake of vitamin B3 (niacin): studies utilizing human and mouse colonic preparations. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 305, G207-G213.	3.4	17
110	Niacin decreases leukocyte myeloperoxidase: Mechanistic role of redox agents and Src/p38MAP kinase. <i>Atherosclerosis</i> , 2014, 235, 554-561.	0.8	17
111	Comparison of gradient gel electrophoresis and zonal ultracentrifugation for quantitation of high density lipoproteins. <i>Journal of Lipid Research</i> , 1985, 26, 1363-7.	4.2	17
112	Dietary fat in experimental nephrotic syndrome: Beneficial effects of fish oil on serum lipids and, indirectly, on the kidney. <i>Life Sciences</i> , 1987, 40, 2317-2324.	4.3	16
113	Optimal Therapy of Low Levels of High Density Lipoprotein-Cholesterol. <i>American Journal of Cardiovascular Drugs</i> , 2003, 3, 53-65.	2.2	15
114	Increments in serum high-density lipoprotein cholesterol over time are not associated with improved outcomes in incident hemodialysis patients. <i>Journal of Clinical Lipidology</i> , 2018, 12, 488-497.	1.5	15
115	Plasma Lipids and Lipoprotein Lipase Activator Property during the Menstrual Cycle. <i>Hormone and Metabolic Research</i> , 1979, 11, 696-697.	1.5	14
116	Pharmacologic augmentation of high-density lipoproteins: mechanisms of currently available and emerging therapies. <i>Current Opinion in Internal Medicine</i> , 2005, 4, 517-522.	1.5	14
117	Association of Serum Paraoxonase/Arylesterase Activity With All-Cause Mortality in Maintenance Hemodialysis Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 4848-4856.	3.6	14
118	Synovial fluid lipoproteins: Review of current concepts and new directions. <i>Seminars in Arthritis and Rheumatism</i> , 1993, 23, 79-89.	3.4	13
119	Statin Therapy Before Transition to End-Stage Renal Disease With Posttransition Outcomes. <i>Journal of the American Heart Association</i> , 2019, 8, e011869.	3.7	13
120	Alterations in reverse cholesterol transport associated with programmable implantable intraperitoneal insulin delivery. <i>Metabolism: Clinical and Experimental</i> , 1994, 43, 665-669.	3.4	12
121	Myeloperoxidase and Atherosclerosis. <i>Current Cardiovascular Risk Reports</i> , 2013, 7, 102-107.	2.0	12
122	Noninvasive tracking of coronary atherosclerosis by electron beam computed tomography: Rationale and design of the Felodipine Atherosclerosis Prevention Study (FAPS). <i>American Journal of Cardiology</i> , 1995, 76, 1239-1242.	1.6	10
123	Identification of an apoC-II variant (apoC-II Bethesda) in a kindred with apoC-II deficiency and type I hyperlipoproteinemia. <i>Journal of Lipid Research</i> , 1988, 29, 273-278.	4.2	10
124	Octogenarian kindred: Hyper-lipoproteinemia. <i>Preventive Medicine</i> , 1978, 7, 1-14.	3.4	9
125	Effect of serum subfractions from peritoneal dialysis patients on Hep-G2 cell apolipoprotein A-I and B metabolism. <i>Kidney International</i> , 1996, 50, 2079-2087.	5.2	9
126	Serum Endocannabinoid Levels in Patients With End-Stage Renal Disease. <i>Journal of the Endocrine Society</i> , 2019, 3, 1869-1880.	0.2	9



#	ARTICLE	IF	CITATIONS
127	Apolipoprotein CII in type I hyperlipoproteinemia. A study in three cases. <i>Translational Research</i> , 1980, 95, 180-7.	2.3	9
128	A micromethod using gas-liquid chromatography for measuring individual fatty acids liberated during interaction of triglyceride-rich lipoproteins and lipoprotein lipase. <i>Analytical Biochemistry</i> , 1980, 107, 432-435.	2.4	8
129	Effect of desialylation of very low-density lipoproteins on their catabolism by lipoprotein lipase. <i>Metabolism: Clinical and Experimental</i> , 1985, 34, 30-35.	3.4	8
130	Characterization of high density lipoproteins from patients with severe hypertriglyceridemia. <i>Atherosclerosis</i> , 1987, 66, 37-43.	0.8	8
131	Albumin inhibits apolipoprotein AI and AII production in human hepatoblastoma cell line (Hep G2): additive effects of oleate-albumin complex. <i>Atherosclerosis</i> , 2000, 149, 43-49.	0.8	8
132	Familial Hypertriglyceridemia in Children: Dietary Management. <i>Pediatric Research</i> , 1977, 11, 953-957.	2.3	7
133	Late hypertriglyceridemia in very low birth weight infants fed human milk exclusively. <i>Journal of Pediatrics</i> , 1987, 111, 466-469.	1.8	7
134	HDL Metabolism in HDL Deficiency Associated with Familial Hypertriglyceridemia: Effect of Treatment with Gemfibrozil. <i>Advances in Experimental Medicine and Biology</i> , 1990, 285, 233-236.	1.6	7
135	Role of adipose tissue in free fatty acid metabolism in hemorrhagic hypotension and shock. <i>Metabolism: Clinical and Experimental</i> , 1975, 24, 855-860.	3.4	6
136	Effect of a high carbohydrate diet on the content of apolipoproteins C-II, C-III and E in human plasma high density lipoprotein subfractions. <i>Atherosclerosis</i> , 1983, 46, 341-352.	0.8	6
137	Niacin Extended-Release Therapy in Phase III Clinical Trials is Associated with Relatively Low Rates of Drug Discontinuation due to Flushing and Treatment-Related Adverse Events. <i>American Journal of Cardiovascular Drugs</i> , 2011, 11, 179-187.	2.2	6
138	Catabolism of human very low density lipoproteins in vitro: a fluorescent phospholipid method for monitoring lipolysis.. <i>Journal of Lipid Research</i> , 1981, 22, 382-386.	4.2	6
139	Catabolism of human very low density lipoproteins in vitro: a fluorescent phospholipid method for monitoring lipolysis. <i>Journal of Lipid Research</i> , 1981, 22, 382-6.	4.2	6
140	Plasma lipids and lipoprotein lipase activating property in women on three different combinations of estrogens and progestins. <i>Biochemical Medicine</i> , 1981, 25, 283-287.	0.5	5
141	Characterization of a monoclonal antibody (HB-22) and development of an ELISA for human apolipoprotein A-I. <i>Clinical Chemistry</i> , 1995, 41, 1150-1158.	3.2	5
142	Cardiovascular outcomes during extended follow-up of the AIM-HIGH trial cohort. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1413-1419.	1.5	5
143	Effect of human high density lipoproteins, anti-apolipoproteins CII and CIII, and hydrolysis of very low density lipoprotein (VLDL) cholesterol ester on VLDL catabolism in vitro. <i>Biochemical and Biophysical Research Communications</i> , 1984, 121, 946-952.	2.1	3
144	[12] Immunochemical methods for quantification of human apolipoprotein C-III. <i>Methods in Enzymology</i> , 1996, 263, 208-218.	1.0	3

#	ARTICLE	IF	CITATIONS
145	Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders. Expert Review of Cardiovascular Therapy, 2008, 6, 1303-1310.	1.5	3
146	Effects of Extended-Release Niacin on Quartile Lp-PLA2 Levels and Clinical Outcomes in Statin-treated Patients with Established Cardiovascular Disease and Low Baseline Levels of HDL-Cholesterol: Post Hoc Analysis of the AIM HIGH Trial. Journal of Cardiovascular Pharmacology and Therapeutics, 2019, 24, 534-541.	2.0	3
147	Tissue lipoprotein lipase, serum, and urinary lipids and lipoproteins in experimental glomerulonephritis of rats (Heymann's nephritis). Biochemical Medicine, 1981, 25, 260-266.	0.5	2
148	Kinetics of lipoprotein lipase interaction with triacylglycerol-rich lipoproteins carrying excess apolipoprotein C-III2. Biochemical Society Transactions, 1985, 13, 131-132.	3.4	2
149	Clinical utility and methods for assessing triglyceride-rich lipoprotein metabolism. Current Opinion in Lipidology, 1991, 2, 379-384.	2.7	2
150	Dyslipidemia treatment: current considerations and unmet needs. Expert Review of Cardiovascular Therapy, 2003, 1, 121-134.	1.5	0
151	Anticipating the evolution of clinical cholesterol guidelines: implications of recent statin intervention trials. Future Cardiology, 2005, 1, 461-471.	1.2	0
152	Diet and High-Density Lipoprotein Metabolism. , 1987, , 557-562.		0